Contact
For business, media, or testing-related inquiries, please get in touch.
ELEVATE INDUSTRY HEALTH & SAFETY STANDARDS WITH C-POLAR™ REVOLUTIONARY PROTECTION AGAINST VIRUSES, MICROORGANISMS, AND POLLENS
REVOLUTIONARY PROTECTION AGAINST VIRUSES, BACTERIA, MOLDS, FUNGI, AND POLLENS
* Based on third-party studies, internal testing, and data from commercial installations
Dr. Michael Mansour, Associate Professor of Medicine at Harvard Medical School, was featured on Canada's CTV News. He discussed technologies like C-POLAR™, which protect against the next pandemic.
Read more
Dr. Michael Mansour featured on CTV News
Media interview
A century ago, a well-ventilated building was considered good medicine. But by the time Covid-19 arrived, our buildings could barely breathe. How do we let the fresh air back in?
Read more
The New War on Bad Air (Article by The New York Times)
Recommended article
C-POLAR was featured on Global News. Senior Director of National Sales, Sam Chung, and Dr. Alan Rabinowitz of St. Paul's Hospital delved into our revolutionary technology.
Read more
C-POLAR featured on Global News with Sonia Sunger
Media interview
This partnership will create infection-resilient environments as C-POLAR captures, inactivates, and eradicates up to 99.99% of viruses, bacteria, molds, and fungi.
Read more
C-POLAR signs cooperation agreement with Northumbria NHS
Press release
Our Chief Science Officer Jeanne Moldenhauer, Co-Chief Innovation Officer Aldrin Or, and Senior Vice President Jackson Tse were published in March's American Pharmaceutical Review.
Read more
C-POLAR team published in The American Pharmaceutical Review
Feature
C-POLAR Ireland is strategically located within the Northumbria Healthcare NHS Manufacturing & Innovation Hub in Northumbria, UK.
Read more
C-POLAR establishes Ireland subsidiary to spearhead EU expansion
News
The study showed C-POLAR™ treated filtration material inactivated 99.4% of pseudo-type SARS CoV-2 and also increased the filtration efficiency of the filtration media from 74.2% to 97.2%.
Read more
Peer-reviewed study confirms effectiveness of C-POLAR filter media
Validation
Who We Are
C-POLAR Technologies, Inc. provides bioprotection solutions.
Studies show our patent-pending technology,
C-POLAR™, captures up to 99.99% of viruses, bacteria, molds, fungi, and pollens.*
We create infection-resilient environments, setting the global standard for health and safety for governments, private enterprises, hospitals, and schools.
*Based on third-party studies, internal testing, and data from commercial installations
Trusted By Global Organizations
BGIS
Global leader in integrated facility management services.
VOLZ
Largest filter manufacturer in Germany with advanced technology .
MIAMI INTERNATIONAL AIRPORT
Miami International Airport is one of the largest airports in North America.
THE GRAND HYATT HK
The Grand Hyatt HK is a five-star, luxury hotel with branches across the world.
HANG LUNG PROPERTIES
Hang Lung Properties is a leading property developer in Hong Kong and Mainland China.
AFL-CIO, METAL TRADES
The Metal Trades Department is part of the AFL-CIO, the largest federation of US unions.
Proven Effective Against
COVID
19
Staphylococcus aureus
Escherichia
coli
Pseudomonas aeruginosa
Coxsackievirus B6
MECHANISM OF ACTION
C-POLAR™ is created using a WHO and UN FAO approved food-additive. Using our patent-pending, proprietary methodology, we apply C-POLAR™ onto selected materials, imbuing them with a stable positive charge. Multiple studies have shown that C-POLAR™ treated materials effectively capture viruses, microorganisms, and pollens with high efficiency.
Our Advantages
C-POLAR™ is based on fundamental physics. Studies show C-POLAR™ can capture up to 99.99% of viruses, microorganisms, and pollens.
- Highly-Effective Against Viruses, Microorganisms, and Pollens
- Versatile Application
- Economical
- Safe For Human Use
Quote from Dr. MICHAEL K. Mansour
